NJ-LARSEN-&-TOUBRO-INFOT
2.11.2022 20:46:36 CET | Business Wire | Press release
Fosfor, the Data Products Unit of Larsen & Toubro Infotech (BSE: 540005, NSE: LTI), today announced that it has been approved as a Snowflake Ready Technology Validation Partner. Achieving this validation confirms Fosfor’s DataOps product, Spectra, and Decision Intelligence product, Lumin, adhere to Snowflake’s best practices around performance, reliability, and security.
Under the Snowflake Ready Technology Validation program, Snowflake audits and validates a company’s native integration with Snowflake based on functional and performance best practices. The audit requires a native connector that has been available for at least six months, as well as a set of joint customers and case studies. With this validation, Fosfor joins a list of prominent product companies that have been approved under this program.
“Efficient access to quality data helps organizations quickly inform strategies and decisions – it is a must-have for our customers," says Tarik Dwiek, Head of Technology Alliances at Snowflake. “Fosfor’s take on monetizing data at speed and scale for enterprises complements Snowflake's commitment to capitalizing on the infinite potential of the Data Cloud and creates a winning proposition for our customers.”
Along with LTI recently being awarded Elite tier partner status and receiving the Delivery Partner of the Year award at the 2022 Snowflake Summit, the Technology Ready designation further reinforces the long-standing partnership between the companies. A growing number of Fosfor customers are realizing the synergistic value created by combining Fosfor’s data and AI capabilities with Snowflake’s Data Cloud.
“The Snowflake-Fosfor partnership is a natural fit in exploding value from Data & AI for enterprises globally and is creating immense value for our joint customers with Fosfor products’ seamless native connectivity to Snowflake. Fosfor products like Spectra are solving major DataOps challenges for enterprises, while Lumin converts data into decision insights with ease for business users,” said Satyakam Mohanty, Chief Product Officer, Fosfor. "We are delighted to be in lockstep with Snowflake to strengthen our valued partnership and in our aligned vision to create limitless business impact for enterprises.”
Snowflake has been a key partner of LTI since 2018, and of the Fosfor product suite since its launch in December of 2021. Click here to learn more about the powerful combination of Fosfor and Snowflake.
About Fosfor
The Fosfor Product Suite is the only end-to-end suite for optimizing all aspects of the data-to-decisions lifecycle. Fosfor helps you make better decisions, ensuring you have the right data in more hands in the fastest time possible. The Fosfor Product Suite comprises of Spectra, a comprehensive DataOps platform; Aspect, a no-code unstructured data processing platform; Optic, a data fabric to facilitate data discovery-to-consumption journeys; Refract, a data science and MLOps platform; and Lumin, a decision intelligence platform. Collectively, the Fosfor suite helps businesses discover the hidden value in their data. The Fosfor Data Products Unit is part of LTI, a global technology consulting and digital solutions company with hundreds of clients and operations in 33 countries. For more information, visit www.fosfor.com.
About LTI:
LTI (NSE: LTI) is a global technology consulting and digital solutions company helping more than 500 clients succeed in a converging world. With operations in 33 countries, we go the extra mile to assist our clients and accelerate their digital transformation journeys. Founded in 1997 as a subsidiary of Larsen & Toubro Limited, our unique heritage gives us unrivalled real-world expertise to solve the most complex challenges of enterprises across all industries. Each day, our team of more than 50,000 LTItes enable our clients to improve the effectiveness of their business and technology operations and deliver value to their customers, employees, and shareholders. Learn more at http://www.lntinfotech.com or follow us at @LTI_Global.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221102005946/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom